Tacrolimus Eye Drops for Anterior Uveitis

(EYETAC Trial)

This trial examines the safety and tolerability of tacrolimus eye drops (tacrolimus ophthalmic solution) for treating active non-infectious anterior uveitis, an inflammation in the front part of the eye. Researchers will test two different strengths of the eye drops to determine which is more effective. These eye drops may benefit individuals who have experienced symptoms of non-infectious anterior uveitis within the last four weeks and require initiation or escalation of steroid eye drop treatment to manage inflammation. As a Phase 2 trial, this research focuses on assessing the treatment's effectiveness in an initial, smaller group of participants.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.

Research has shown that tacrolimus eye drops are generally safe for treating eye inflammation. Studies have demonstrated that tacrolimus effectively reduces inflammation in conditions like allergic conjunctivitis, which is similar to the focus of this trial on anterior uveitis. In several studies, patients used tacrolimus without major issues.

For instance, one study found that tacrolimus eye drops were well-tolerated by patients with allergic eye conditions. Another study showed that even a low concentration of tacrolimus eye drops reached effective levels in the eye, indicating it works without causing harm.

Unlike standard treatments for anterior uveitis, which typically involve corticosteroids, Tacrolimus eye drops offer a unique approach by using an immunosuppressant that targets T-cells to reduce inflammation. This treatment is exciting because it might minimize steroid-related side effects, such as increased eye pressure and cataracts, which are common with long-term steroid use. Additionally, the trial explores both low and high doses, potentially offering tailored options for different levels of disease severity. Researchers are hopeful that this alternative could provide a safer and equally effective option for managing anterior uveitis.

Research has shown that tacrolimus eye drops may help treat anterior uveitis, an inflammation in the eye. This trial will compare different dosages of tacrolimus ophthalmic solution. Studies have found that tacrolimus effectively reduces inflammation in various eye conditions, including non-infectious uveitis. In one study, 65.6% of people with active uveitis experienced improvement, with their condition becoming inactive, often within 1.5 months of using tacrolimus. Additionally, tacrolimus has successfully treated other inflammatory eye diseases, indicating its potential to control inflammation more broadly. Tacrolimus is known for its strong ability to suppress the immune system, which helps reduce the immune response that causes eye inflammation.¹³⁶⁷⁸